Key Takeaways
- • Sofina stock trades at EUR 245.40 with a market capitalization of EUR 8.30 billion as of August 24, 2026, demonstrating price stability in the mid-EUR 240s range with minimal volatility between regular and after-hours sessions (EUR 245.50).
- • The stock has recorded a 12.78% price movement over the recent reporting period, indicating meaningful but measured performance volatility despite steady current-level trading.
- • Sofina's valuation is supported by its diversified private equity portfolio, which includes direct investments in approximately 80 companies with a net asset value of approximately EUR 10.3 billion as of end-December 2024.
- • Recent portfolio activity includes participation in growth-stage deals such as the Berry Street-Healthify merger, reflecting continued active deployment across the nutrition and healthcare technology sectors.
- • Sofina's top 10 direct investments represent 29% of portfolio fair value, with notable stakes in ByteDance, Cognita, Nuxe, and Drylock, anchoring the company's exposure to high-growth private enterprises.
Summary
Sofina SA, the Belgium-based investment company, maintained steady trading around EUR 245.40 per share on August 24, 2026, with minimal divergence between regular-session and after-hours pricing, suggesting investor confidence and stable demand at current valuation levels. The stock's EUR 8.30 billion market capitalization reflects the company's position as a significant player in private equity and growth-stage investment management.
The recent 12.78% price movement underscores volatility in the broader market environment, yet the tight trading range around EUR 245 indicates consolidation at current levels. The minimal gap between the EUR 245.40 regular close and EUR 245.50 after-hours quote suggests limited immediate pressure or speculative positioning around this price level, which may appeal to institutional investors seeking relatively stable entry or adjustment points.
Sofina's valuation is fundamentally supported by its substantial private equity portfolio. As of end-December 2024, the company reported a net asset value of approximately EUR 10.3 billion across direct investments in roughly 80 companies. The portfolio remains concentrated, with the 10 largest investments representing 29% of fair value, including significant stakes in ByteDance, Cognita (an education platform), Nuxe (luxury skincare), and Drylock Technologies. This concentration reflects Sofina's strategic focus on high-conviction, growth-oriented positions rather than a diversified index approach.
Recent deal activity within Sofina's portfolio demonstrates ongoing deployment and value creation momentum. The company participated in funding rounds for growth-stage companies, notably including exposure to the Berry Street-Healthify nutrition and health technology combination, indicating active engagement in emerging sectors aligned with long-term consumer and digital health trends. This portfolio activity reinforces the narrative that Sofina's current valuation reflects both its existing asset base and management's continued capacity to source and execute on attractive private equity opportunities.
The recent 12.78% price movement underscores volatility in the broader market environment, yet the tight trading range around EUR 245 indicates consolidation at current levels. The minimal gap between the EUR 245.40 regular close and EUR 245.50 after-hours quote suggests limited immediate pressure or speculative positioning around this price level, which may appeal to institutional investors seeking relatively stable entry or adjustment points.
Sofina's valuation is fundamentally supported by its substantial private equity portfolio. As of end-December 2024, the company reported a net asset value of approximately EUR 10.3 billion across direct investments in roughly 80 companies. The portfolio remains concentrated, with the 10 largest investments representing 29% of fair value, including significant stakes in ByteDance, Cognita (an education platform), Nuxe (luxury skincare), and Drylock Technologies. This concentration reflects Sofina's strategic focus on high-conviction, growth-oriented positions rather than a diversified index approach.
Recent deal activity within Sofina's portfolio demonstrates ongoing deployment and value creation momentum. The company participated in funding rounds for growth-stage companies, notably including exposure to the Berry Street-Healthify nutrition and health technology combination, indicating active engagement in emerging sectors aligned with long-term consumer and digital health trends. This portfolio activity reinforces the narrative that Sofina's current valuation reflects both its existing asset base and management's continued capacity to source and execute on attractive private equity opportunities.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.